Topics:
Lung Cancer • Breast Cancer • Thoracic Malignancies • Medical Oncology • Her2+ • Journal Club ft. NEJM publications
How do you interpret efficacy of trastuzumab deruxtecan based on HER2 mutation type and/or level of HER2 overexpression?
How and when do you plan to perform HER2 testing in patients with NSCLC?
Answer from: Medical Oncologist at Academic Institution
In the phase 2 DESTINY-Lung01 study, the majority of the HER2 mutation was at exon 20 and were insertion mutations. There were other rare HER2 alterations such as exon 19 and extracellular domain mutation in exon 8 that also responded to trastuzumab deruxtecan. Some of these patients had their HER2 ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The results with HER2 mutations are more reliable than the protein expression. I perform HER2 testing with my NGS at diagnosis because we did have some trials.